SU5416, 10 mg

STEMCELL Technologies supplies this small molecule as a broad-spectrum inhibitor of receptor tyrosine kinases, best known as an ATP-competitive inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2; KDR/Flk-1). Reported IC₅₀ values include KDR (IC₅₀ = 1 µM), PDGFR (IC₅₀ = 20 µM), KIT (IC₅₀ = 30 nM), RET (IC₅₀ = 170 nM), FLT-3 (IC₅₀ = 160 nM), ABL (IC₅₀ = 11 µM), and ALK (IC₅₀ = 1.2 µM), while EGFR and FGFR are not inhibited (IC₅₀ > 100 µM).

Provided as a crystalline solid, the compound has the chemical formula C₁₅H₁₄N₂O and a molecular weight of 238.3 g/mol. Reported purity is ≥ 98%, and the CAS number is 204005-46-9. Alternative names include NSC 696819, Semaxinib, Sugen 5416, and VEGFR 2 Kinase Inhibitor. The product is stable at -20°C as supplied and should be protected from prolonged exposure to light. Solubility data support stock solutions in DMSO (≤ 40 mM) and absolute ethanol (≤ 1 mM); the compound has low solubility in aqueous media.

Published applications span immunology, cancer research, and disease modeling. In immunology, the compound inhibits TGFβ1 activation and delays wound healing in rats. In cancer research, it prevents angiogenesis, thereby inhibiting tumor growth and vascularization, and inhibits RET-mediated transformation of NIH-3T3 mouse fibroblasts and Ba/F3 mouse pro-B cells. In disease modeling, the compound causes pulmonary hypertension in the SuHx rat model of pulmonary arterial hypertension when combined with hypoxia.